Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer
Yago Nieto(The University of Texas MD Anderson Cancer Center), Roy B. Jones(The University of Texas MD Anderson Cancer Center), Nelson J. Chao(Duke University), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), David A. Rizzieri(Duke University), Anna E. Barón(Colorado School of Public Health), Peter A. McSweeney(Mesoblast (United States)), Steve Matthes(University of Colorado Boulder), James J. Vredenburgh(Duke University), Scott I. Bearman(University of Washington), Christina Gasparetto(Duke Medical Center)
Cited by 16
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2020|739